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Synopses
Burkholderia (previously known as
Pseudomonas) cepacia, a nutritionally versatile,
gram-negative organism, was first described in
1949 by Walter Burkholder of Cornell University,
as the phytopathogen responsible for a bacterial
rot of onions (1) (Figure 1). Ironically, B. cepacia
is now being considered by agricultural microbi-
ologists as an agent to promote crop growth.
B. cepacia is inherently resistant to multiple
antibiotics, can metabolize diverse substrates,
and is found in soil and in moist environments.
The organism has a particular predilection for
the lung in patients with cystic fibrosis (CF) and
has emerged as an important opportunistic
human pathogen in hospitalized and
immunocompromised patients (2,3).
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In the past 2 decades, Burkholderia cepacia has emerged as a human pathogen
causing numerous outbreaks, particularly among cystic fibrosis (CF) patients. One
highly transmissible strain has spread across North America and Britain, and another
between hospitalized CF and non-CF patients. Meanwhile, the organism has been
developed as a biopesticide for protecting crops against  fungal diseases and has
potential as a bioremediation agent for breaking down recalcitrant herbicides and
pesticides. However, B. cepacia is inherently resistant to multiple antibiotics; selection
of strains “safe” for environmental application is not at present possible phenotypically
or genotypically; molecular epidemiology and phylogenetic studies demonstrate that
highly transmissible strains emerge randomly; and the organism has a capacity for rapid
mutation and adaptation (facilitated by numerous insertion sequences), and a large,
complex genome divided into separate chromosomes. Therefore, the widespread
agricultural use of B. cepacia should be approached with caution.
Figure 1. B. cepacia causes an onion rot known as slippery skin
(1). The onions shown were inoculated with three strains of B.
cepacia. Rot occurred in onion1 (left), which was inoculated with
strain originally isolated from onions. Rot did not occur with en-
vironmental isolates tested or with strains from CF lung.
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B. cepacia as a Human Pathogen
In CF Patients
CF is a recessively transmitted genetic
disease that occurs in approximately 1 in 2,500
Caucasians (carrier frequency of 1 in 25). The
condition is characterized by a generalized
dysfunction of the exocrine glands, giving rise to
a broad spectrum of clinical syndromes,
especially malabsorption due to pancreatic
insufficiency and chronic progressive lung
disease giving rise to bronchiectasis. B. cepacia is
associated with increased illness and death
among CF patients. In the early 1980s, the
organism emerged as a major threat, causing
superinfection in as many as 40% of patients in
some CF centers (4-6). While in some patients
indolent pulmonary infection occurs with only
gradual deterioration in lung function similar to
that associated with Pseudomonas aeruginosa,
approximately 35% of B. cepacia–infected
patients contract accelerated pulmonary deterio-
ration or fulminant, necrotizing pneumonia with
rapidly fatal bacteremia (3,7-10), sometimes
referred to as “cepacia syndrome” (7). Unlike
infection with P. aeruginosa, B. cepacia infection
significantly increases death rates among CF
patients (11) at all levels of lung function.
Over the last 20 years, CF survival rates have
increased as a result of improved treatment, the
median length of survival increasing from early
childhood to more than 29 years. As a result,
approximately one third of CF patients are
adults. Pulmonary infection causes the most
illness and ultimately more than 90% of CF-
related deaths. B. cepacia’s emergence as a
pathogen coincided with social and medical
grouping of CF patients in specialized units,
clinics, and social groups. Studies subsequently
demonstrated that social contact between CF
patients was an important factor in transmission
of B. cepacia (12).
The threat of B. cepacia infection led to severe
control measures, affecting not only the
treatment but also the social and family lives of
CF patients. CF centers adopted stringent
infection control policies, assuming that all B.
cepacia isolates were highly transmissible
(13,14). CF summer camps in North America
were closed, and many lung transplant centers
ceased to accept B. cepacia–infected CF patients
as transplant candidates.  Newly formed national
and international associations for CF adults and
CF families (providing conferences, holidays, and
support groups) addressed the issue of B. cepacia
transmission by abandoning many activities and
adopting exclusion and segregation measures (13).
Numerous CF-associated B. cepacia epidem-
ics have now been described, and the epidemic
strains have been characterized (15-18). One
particular highly transmissible strain, epidemi-
cally spread within and between CF centers on both
sides of the Atlantic, carries the cblA gene (18). This
gene encodes for the major structural subunit of
unique mucin binding cable pili (4). These
enormously long pili (radiating 2 to 4 microns) are
peritrichously arranged and are intertwined to
form cablelike structures that adhere to CF mucin
(4,18) (Figure 2).  This cblA+ strain has spread
across Canada and has now been isolated in 50% of
CF centers in the United Kingdom (19). Another
strain of B. cepacia has spread among CF centers in
four regions of France (20).
However, it has become clear that transmissi-
bility varies markedly from strain to strain, and
that most strains are not involved in epidemics
but appear to be independently acquired and
show no evidence of transmission. For example,
in 8 years no cases of transmission were detected at
the University of North Carolina CF center, despite
clinical and social contact between patients and the
absence of stringent infection control measures
(21). Independent acquisition of B. cepacia with no
evidence of transmission between CF patients was
also reported from Denmark (22). Lack of
transmission of some strains has also been observed
between siblings with CF (23).
In Patients Without CF
B. cepacia was first reported as a human
pathogen causing endocarditis in the 1950s.
Since then the organism has caused numerous
catheter-associated urinary tract infections,
wound infections, and intravenous catheter–
associated bacteremias. In 1971, it was reported
as the causative organism of “foot rot” in U.S.
troops on swamp training exercises in northern
Florida; it was also isolated from troops serving in
the Mekong Delta, Vietnam (24).
In the 1980s the number of nosocomial
infections with B. cepacia increased markedly,
with deaths particularly associated with lung
infections (25). Numerous small focal hospital
outbreaks involving non-CF patients have
usually been due to a contaminated common
source, such as disinfectant preparations or
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Figure 2. Transmission electron micrograph of Toronto/Edinburgh epidemic clone of B. cepacia express-
ing CF mucous-binding Cbi adhesin pili. High resolution was achieved by using a JEOL 100CX electron
microscope and negative staining. Reprinted with permission from Richard Goldstein and Journal of
Bacteriology (J Bacteriol 1995;177:1039-52).
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intravenous solutions (2,26,27). The organism’s
unusually broad metabolic capabilities, which
enable it to survive and proliferate in water-
based environments, probably account for its
propensity to cause nosocomial outbreaks (2,27-
29). Because of its resistance to multiple
antibiotics, once acquired, the organism can be
difficult to treat.
B. cepacia is rarely found in the non-CF
patient (30); however, when it is found the
organism can spread to and from CF patients.
Transmission between CF and non-CF patients
has been associated with serious illness and
death (31;Holmes et al., unpub. data) and
presents a greater nosocomial threat than
previously recognized. In addition, although B.
cepacia is not a common commensal organism,
hospitalized patients without CF may harbor it
and pose an infection threat to vulnerable CF
patients. This possible source of infection may
account for the known association between
hospitalization and of B. cepacia infection  (32).
B. cepacia may be underreported because
selective media for B. cepacia, which greatly
increase the yield (33,34), are rarely used
except in specimens from CF patients.
B. cepacia as an Agricultural Agent
While emerging as a human pathogen, B.
cepacia has attracted intense interest from the
agricultural industry as a possible biologic
control agent. The organism, which has been
shown to have remarkable potential as an agent
for both biodegradation and biocontrol, is being
considered as a plant-growth-promoting
rhizobacterium (23,35-43).
B. cepacia has extraordinary metabolic
versatility and can degrade chlorinated aromatic
substrates (toxic compounds found in complex
pesticides and herbicides, some with carcinogenic
potential) for use as carbon energy sources. One
important toxic compound degraded by B.
cepacia is 2,4,5 chlorophenoxy acetic acid (2,4,5-
T), a potent herbicide that is not easily
biodegradable and persists for long periods in the
environment (37).
B. cepacia can also antagonize and repress
many soilborne plant pathogens. It can prevent
leaf and stem blight caused by the fungus
Alternaria by inhibiting spore germination.
Economically important crop diseases such as
blight due to A. solani and the blight caused by A.
brassicae and A. brassicola, which affects the oil-
producing plants rape and canola, can be
controlled by B. cepacia. The organism is also
being used to prevent the blight of ginseng plants
due to A. panax (41) and is effective against the
fungus Aphanomyces euteiches, which causes
root rot in peas, alfalfa, and snap beans (39,40). It
can prevent Pythium diseases of cucumber and
peas, and Rhizoctonia solani stem rot of
poinsettia (42). To prevent these plant diseases,
B. cepacia provides a seemingly environmentally
friendly alternative to potent and toxic fungi-
cides, which cannot be broken down in the
environment.
The forestry industry also sustains large
economic losses from the pathogenic effects of
fungi such as Fusarium, Pythium, Rhizoctonia,
Cylindrocarpum, and Botrytis. These widespread
fungal pathogens cause seedling loss in nurseries
and may kill or stunt transplanted seedlings. A
strain of B. cepacia has been developed as a
successful seed and root inoculant, which can
suppress these fungi on a variety of conifers (43).
Numerous patents are being sought for
specific agricultural applications of different
strains of B. cepacia. The ecologic and economic
benefits could be enormous if the organism’s
antifungal activity is used to enhance crop yields
and reduce the need for pesticides and its ability
to degrade complex herbicides and pesticides is
harnessed for bioremediation.
Molecular Epidemiology of B. cepacia
Evolution of Highly Transmissible Strains
B. cepacia isolates are closely related (a
panmictic population structure) (18,31,44) and
epidemic isolates are scattered throughout
(18,31), as demonstrated by rrn-based phylogenic
trees, which include large numbers of environ-
mental and clinical isolates. Such a phylogeny
indicates that in B. cepacia strains, genetic changes
conferring high transmissibility are occurring at
random, or, given the right epidemiologic
circumstances, random environmental strains are
innately highly transmissible. In addition, the
widespread geographic distribution of different
epidemic strains of B. cepacia would also suggest
that highly transmissible strains are emerging
independently and randomly.
Taxonomy
Isolates presumptively identified as B.
cepacia belong to at least five genomovars
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(23,45,46). This group of phenotypically similar
subpopulations is referred to as the B. cepacia
complex (6,46). After multiphasic taxonomic
analysis, the species names B. multivorans and
B. vietnamiensis have been proposed for
genomovars II and V, respectively (45). The
pathogenic and epidemic potential of each of
these subpopulations of the B. cepacia complex
requires further examination. Although it
appears that strains associated with cepacia
syndrome belong to genomovar III (46), isolates
belonging to each of these five genomovars have
been cultured from CF patients.
The Unusual Genome
B. cepacia’s capacity to propagate as an
environmental microbe and as an opportunistic
pathogen may be due to its possession of an
unusually large (more than four times that of H.
influenzae, two times that of E. coli, and half
again as large as  P. aeruginosa), complex, and
variable genome. The genome contains numerous
insertion sequences and is divided into one to four
circular replicons (47,48). A few other bacterial
species of agricultural and medical importance
also have multiple chromosomes: Brucella
melitensis, B. abortus, B. suis, B. ovis,
Rhodobacter sphaeroides, and Agrobacterium
tumefaciens (49-51).
This unusual genomic arrangement may
account for B. cepacia’s nutritional versatility
and adaptability. Such a division of genomic
content would allow for high levels of homologous
and illegitimate recombination. The resultant
chromosomal rearrangements and associated
mutations could provide a basis for spontaneous
“pulsed” evolutionary spurts, such as that seen
from soil to the CF lung, suited for rapid
adaptation to radical changes in environmental
growth conditions.
Selection of Strains for Agricultural Use
Because evolution of highly transmissible
strains occurs randomly and transmission of B.
cepacia between CF and non-CF populations can
cause severe illness and death, the deliberate
widespread environmental application of strains
of this organism should be considered carefully.
Although B. cepacia does not appear to survive on
dry surfaces for more than 1 week, it can survive
for many months in water. The agricultural
application of B. cepacia will lead to environmen-
tal and water contamination and increased
human exposure. In addition to medical,
metabolic, and taxonomic issues, increasing
knowledge of B. cepacia raises important
ecological issues, including the evolution of
pathogenicity and multiresistant environmental
bacteria through horizontal gene transfer. The
agricultural use of B. cepacia risks this hazard of
horizontal gene transfer between the strains
applied and existing soil organisms and the
subsequent emergence of pathogenic, highly
resistant organisms.
Recently, in an attempt to assess the human
risk associated with the use of rhizophere isolates
as field inoculants, two clinical isolates of
different strain types from two CF patients and
two agricultural isolates from the rhizopheres of
rice and maize were examined (38). The clinical
isolates had identical 16S ribosomal rDNA
sequences, but differences were seen between the
soil isolates and clinical isolates. The results were
presented as evidence of evolutionary divergence
of the rhizophere isolates from their clinical
counterparts. Alternatively, in the light of the
multiple replicon model, this difference in 16S rrn is
most likely due to the multiple replicons carrying
varying sequences of the 16s gene. Furthermore,
evidence based on four isolates alone is inadequate
to support the safe application of rhizophere
isolates. We have seen diversity among 16s rrn that
is unrelated to source in a large collection of B.
cepacia isolates (Holmes, Truong, Geisselsoder,
Goldstein, unpub. data).
The possibility of highly virulent strains of B.
cepacia with the potential to survive intracellu-
larly exists if the organism acquires virulence
genes from B. pseudomallei, a very closely related
pseudomonad. B. pseudomallei is a soil saprophyte
that gives rise to melioidosis, a life-threatening
tropical disease seen mostly in Southeast Asia.
The disease has a broad clinical spectrum and can
remain dormant for years before giving rise to
sepsis and death. The pattern of disease produced
by B. pseudomallei may warn of a spectrum of
clinical consequences from B. cepacia acquisition.
The transfer of genetic material between these
two closely related organisms in the environment
is highly probable, with the subsequent emer-
gence of a hybrid pathogen. This speculation is
supported by recent detection of insertion
sequences within B. pseudomallei that have been
identified in B. cepacia, including an isolate
belonging to the highly transmissible transatlan-
tic epidemic lineage (18,52).
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With the potential emergence of diseases
related to new and developing practices in the
food and agricultural world, it seems prudent
that communication and information sharing
between medical microbiologists, agricultural
microbiologists, and public health professionals
be optimized and promoted. Meanwhile, it is
impossible to identify, phenotypically or geno-
typically, strains of B. cepacia that could safely be
used in agriculture. Even if environmental strains
incapable of human infection could be identified,
their potential to evolve into human pathogens
remains. Current molecular genetic evidence
indicates that the deliberate environmental
distribution of the organism might pose a hazard to
human health, regardless of which particular
strains are selected. Until more is known about the
organism and the risks from environmental
application, a moratorium should be called on the
widespread use of B. cepacia in agriculture.
This work was supported in part by a research grant
award to RG from the National Institutes of Health (NIDDK
RO1 DK50838).
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